Kim L.R. Brouwer, Pharm.D., Ph.D., is the William R. Kenan Jr. Distinguished Professor in the Division of Pharmacotherapy and Experimental Therapeutics of the UNC Eshelman School of Pharmacy, associate dean for research and graduate education, and a professor in the curriculum in toxicology.
Faculty and Staff
Yanguang Cao, Ph.D., joined the UNC Eshelman School of Pharmacy as an assistant professor in the division of Pharmacotherapy and Experimental Therapeutics. He received his Ph.D. at China Pharmaceutical University. Prior to joining the School, Cao served as a research assistant professor at SUNY Buffalo for two years after completing a postdoctoral training program at SUNY, Buffalo.
Amber Cipriani, Pharm.D., joined the UNC Eshelman School of Pharmacy as a clinical assistant professor in the Division of Pharmacotherapy and Experimental Therapy. Proctor’s appointment is cofunded by UNC Hospitals, where she serves as a clinical oncology specialist in thoracic oncology.
Amanda Corbett, Pharm.D., is a clinical associate professor in the Division of Pharmacotherapy and Experimental Therapeutics and the Global Pharmacology Coordinator for the UNC Institute of Global Health and Infectious Diseases. Her expertise are in HIV, antiviral, and opportunistic infection clinical pharmacy and ethnopharmacology. She has extensive experience in developing countries and more recently in integrative medicine practices.
Daniel Crona, Pharm.D., Ph.D., joined the UNC Eshelman School of Pharmacy in 2015. His translational research program focuses on how genetic variations can lead to differences in the pharmacokinetics and pharmacodynamics of therapeutic treatments used in oncology, and how inter-individual differences in clinical pharmacology measures can affect survival and drug toxicity phenotypes.
Julie Dumond, Pharm.D., M.S., is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. Her primary research interest is the pharmacokinetics/pharmacodynamics of antiretrovirals. She is currently conducting a clinical study in aging, HIV-infected subjects to explore the effects of cellular aging and frailty on antiretroviral toxicity and efficacy.
Bob Dupuis is a clinical professor of pharmacy in the UNC Eshelman School of Pharmacy. His responsibilities include teaching and coordinating coursework in integrative pharmacotherapy, clinical pharmacology, nephrology and transplant pharmacotherapeutics. Dupuis is also Director of the DPET Fellowship program, and advises and works with graduate, PharmD students and fellows on their research endeavors.
Amber Frick, Pharm.D., Ph.D., is a clinical assistant professor with the Division of Pharmacotherapy and Experimental Therapeutics. Her main responsibilities at the School are to develop an expertise in the implementation and assessment of new approaches to and best practices in teaching while also taking part in collaborative teaching activities.
ACCEPTING DOCTORAL STUDENTS
Daniel Gonzalez, Pharm.D., Ph.D., is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. His research interests include pediatric clinical pharmacology and the application of mathematical modeling and simulation techniques to characterize the pharmacokinetics and pharmacodynamics of drugs, guide dosage selection, and improve drug safety in children.
The Heinzen Lab focuses on the genetic and genomic basis of epilepsy disorders, including analyses of the role of germline mutations, somatic mutations, and how regulation of the cellular transcriptome influences the risk and presentation of seizures. In collaboration with a number of investigators in neurology, neuropathology, and neurosurgery, my group is to studies the role of somatic mutations in epilepsy and other neurological diseases.
Klarissa Jackson, Ph.D. joined the faculty at the UNC Eshelman School of Pharmacy as an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics in 2019. Her research interests focus on drug metabolism and toxicology to better understand the mechanisms and risk factors of adverse drug reactions and improve drug safety.
Dr. Kashuba’s research focuses on the clinical pharmacology of drugs used in the treatment, prevention, and cure of HIV infection. She is working on optimizing dosing strategies for HIV prevention including the role of sex and ethnicity, characterizing drug distribution in putative viral reservoirs using mass spectrometry imaging, determining predictors of drug tissue distribution, and developing in vitro models for optimizing combination therapy for HIV cure.
Benyam Muluneh, Pharm.D., is a clinical assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. Muluneh coordinates a course in the integrative pharmacotherapy series and teaches in several PharmD courses. His research interests include optimization of pharmacotherapy in leukemias through the precision dosing initiative and a multidimensional approach to understanding and improving adherence to oral oncolytics. Muluneh also leads the school’s collaborations with Addis Ababa University in Ethiopia with a focus on hematology/oncology including serving as a GPS preceptor.
Herb Patterson, Pharm.D., is a professor and the interim chair of the Division of Pharmacotherapy and Experimental Therapeutics and a research professor of medicine at the University of North Carolina at Chapel Hill. His clinical research focuses on drugs used in heart failure.
Adam Persky is a professor in the Division of Pharmacotherapy and Experimental Therapeutics. He teaches physiology and pharmacokinetics. His research focuses on translating the science of learning and memory into practical application in the classroom and experiential settings.
Wayne Pittman, M.S. Pharm, is an associate professor in the Division of Pharmacotherapy and Experimental Therapeutics and is the Associate Dean for Facilities Planning and Resource Analysis for the UNC Eshelman School of Pharmacy. His research focuses on the clinical and patients’ use of medications used in treating hypertension.
Gauri Rao, Pharm.D., M.S., is an assistant professor in the Division of Pharmacotherapy and Experiential Therapeutics. Rao’s principal research interests surround quantitative systems pharmacology, and she is working to understand the processes of infectious diseases.
Tim Wiltshire, Ph.D., is an associate professor in the Division of Pharmacotherapy and Experimental Therapeutics and Director of the UNC Center for Pharmacogenomics and Individualized Therapy. The major focus of his laboratory and CPIT is to take the pharmacogenetic knowledge we already have and develop approaches for that information to be used effectively in clinical practice.
William Zamboni, Pharm.D., Ph.D., is an associate professor in the Division of Pharmacotherapy and Experimental Therapeutics and UNC Lineberger Comprehensive Cancer Center. He is the director of UNC GLP Bioanalytical Facility and the director of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab. His research interests focus on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimization of the chemotherapeutic treatment of cancer.
Jacqueline Bezençon, Ph.D., is a Research Assistant Professor in the Division of Pharmacotherapy and Experimental Therapeutics. Her research interests are disease- and drug-mediated alterations in transport of drugs and endogenous compounds and its impact on drug disposition and toxicity.
Rachel Church, Ph.D., researches ways to broaden the use and understanding of newer biomarkers by leading the Hamner-UNC Organ Injury Biomarker Core. The goal of this core is to assist investigators in all aspects of research studies in which injury to the liver, kidney, and/or heart is suspected.
Mackenzie Cottrell, Pharm.D., M.S. is a research assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. Her research focuses on describing pharmacokinetic/pharmacodynamic relationships in mucosal tissues for antiretrovirals being used in HIV prevention and cure interventions.
Dong Fu, Ph.D., is a Research Assistant Professor in the Division of Pharmacotherapy and Experimental Therapeutics. His research interests are liver cell biology and hepatic pharmacology, especially, the cellular processes and the mechanisms that are related to hepatocyte polarization, hepatic transporters trafficking, bile acid signaling, drug-induced mitochondrial and hepatocellular injury and lipids metabolism in hepatocytes.
Dr. Lucas has been involved in cancer research for > 11 years and translational/clinical studies of anticancer agents for > 7 years. He has been highly trained to perform the detailed analytical and pharmacology studies required for the translational development of such agents. He also has experience performing the pharmacokinetic and pharmacodynamic analyses of drugs as part of preclinical and clinical studies. His research focuses on the development of phenotypic probes and chemical screens to translate preclinical results into clinical practice in order to create new paradigms to individualize nanoparticle and antibody-based therapies. He also leads the development of new analytical platforms to measure drugs within different cells types as part of in vivo studies. In addition, he has extensive experience with the submission of IACUC and IRB protocols and handling the regulatory process for protocols at UNC.
Merrie Mosedale, Ph.D., is a research assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. Mosedale is also the assistant director of the Institute for Drug Safety Sciences where she leads the Translational Pharmacogenomics Research Program. Through partnerships with pharmaceutical companies and academic scientists, Mosedale is working to solve safety problems by integrating cutting-edge pharmacogenomics approaches with novel in vivo, in vitro, and in silico platforms.
Dr. Rosen’s research focuses on the development of methods to measure intracellular distribution of therapeutics and their metabolites in a variety of biological matrices using mass spectrometry imaging. He is currently quantifying the penetration of drugs relevant to HIV treatment and eradication into putative viral reservoirs, and combining this approach with traditional imaging modalities to evaluate efficacy of experimental treatment regimens.
Kirkwood Adams, MD
Adams is an associate professor of medicine and radiology at the University of North Carolina. He specializes in heart failure, nuclear cardiology, cardiac transplantation, and general cardiology.
Hugh A. Barton, PhD
Barton currently works as a consultant for Barton Systems Pharmacology and Toxicology. His area of expertise includes translational modeling and stimulation, pharmacokinetics, and dynamics and metabolism.
Robert R. Bies, PharmD, PhD
Bies is an associate professor in the department of pharmaceutical sciences at the University of Buffalo School of Pharmacy and Pharmaceutical Sciences. He is involved in the field of pharmacometrics.
William Brock, PhD
Brock is the founder of Brock Scientific Consulting LLC which provides expert-led toxicology services to the pharmaceutical, consumer product, food, medical device, and chemical industries.
Gilbert Burckart, PharmD
Burkhart is the associate director of pediatrics in the office of clinical pharmacology at the US Food and Drug Administration.
Scott Clark, PhD
Clark, of SCSClark Networks, specializes in pharmacogenomics.
Austin Combest, PharmD
Combest is the senior director of information and clinical science in global product development for PPD.
Ronald Fleming, PharmD
Fleming’s research area is oncology and provides expertise in the pharmaceutical industry.
John Edgar French, PhD
French is involved in research collaborations with DPET in the area of toxicology.
Giulia Ghibellini, PhD
Ghibellini is the director of clinical pharmacology at Teva Pharmaceuticals. Her research expertise is in the fields of pharmacokinetics and clinical pharmacology.
Natalia Gonzalez, MD
Gonzalez is involved in research in the area of neurology and clinical drug development.
Allison H. Harrell, PhD
Harrell is a geneticist at National Toxicology Program (NIH/NIEHS). Her area of research covers toxicology and drug-induced liver injury.
Alan Higgins, PhD
Higgins, of Baskerville Consulting, is an expert in the field of preclinical drug development.
Howard L. McLeod, PharmD
McLeod’s research is focused on pharmacogenomics and individualized therapy.
Alison A. Motsinger-Reif, PhD
Motsinger-Reif’s research at the North Carolina State University is focused on pharmacogenetics and bioinformatics.
Jai Narendra Patel, PharmD
At the Carolina HealthCare System’s Levine Cancer Institute, Patel is involved in preclinical drug development research.
Kenneth Phares, PhD
Phares has extensive experience in the pharmaceutical industry, specifically in the areas of preformulation, formulation development, and bioanalytical method development.
Matthew Tyler Pletcher, PhD
Pletcher is the head of Rare Disease Discovery at Roche. His research is focused on genetics and pharmacogenomics.
Bob Powell, PharmD
Powell is a clinical pharmacologist who is interested in developing better dosing strategies in emerging markets with the goal of making drugs safer and more effective.
Virginia Schmith, PhD, FCP
Schmith has extensive research experience in clinical pharmacology and pharmacometrics.
Todd Schwartz, DrPH
Schwartz is a research associate professor of biostatistics at the UNC Gillings School of Global Public Health.
Russell Thomas, PhD
Thomas is the director for the EPA’s National Center for Computational Toxicology. His research is focused on genomic biology and bioinformatics.
Daniel Weiner, PhD
Weiner’s expertise is in the field of pharmacometrics and pharmaceutical biostatistics.
Maciej Jan Zamek-Gilszczynski, PhD
Zamek-Gilszczynski is a scientific director at GlaxoSmithKline. His research focuses on preclinical drug development.
Zhiynag Zhao, PhD
Zhao is the Chief Scientific Officer at Alliance Pharma. His area of research is pharmacokinetics and drug metabolism.
James Heyward Hull, Pharm.D., M.S., is a professor emeritus with the Division of Pharmacotherapy and Experimental Therapeutics. He has expertise in design of clinical drug trials, optimization of study efficiency through better design & analysis strategies and techniques for analysis of concentration-response data.